Two platforms measuring placental growth factor

Gemcitabine (PlGF) and soluble FMS-like tyrosine kinase-1 (sFlt-1), either singly (i.e., PlGF) or as a ratio (e.g., sFlt-1/PlGF ratio) [134] and [135] are being licenced in North America. 1. Women should be screened for clinical risk markers of preeclampsia from early pregnancy (II-2 C; Low/Strong). Of the many risk markers for preeclampsia (Table 5) [99], [111], [136], [137], [138], [139], [140], [141], [142], [143], [144], [145], [146], [147], [148], [149], [150], [151], [152], [153], [154], [155], [156], [157], [158], [159], [160], [161], [162], [163] and [164], many are known at booking and increase the risk of preeclampsia two- to fourfold [165]. The strongest

of these are previous preeclampsia, antiphospholipid antibody syndrome, pre-existing medical conditions, and multiple pregnancy (all bolded in Table 5). For other risk markers, the strength of the association is less well established, less consistent, or the marker becomes available in the second or third trimesters (see Y-27632 mw below). With prior preeclampsia (of any type), the risk of recurrent preeclampsia in a subsequent pregnancy varies widely (Modulators median 15%) [169], [170], [171], [172], [173], [174], [175], [176], [177], [178], [179], [180], [181], [182], [183], [184], [185], [186], [187], [188], [189], Amisulpride [190] and [191], as does “severe” recurrent preeclampsia (median 15%) [170], [175],

[176], [181], [182], [184], [188], [192], [193], [194] and [195]. Recurrence is more likely when prior preeclampsia was: of early onset [184], [188] and [194], “severe” [169] and [187], or complicated by eclampsia [192], [193] and [196] or HELLP syndrome [176], [177], [182] and [188]. Higher BMI in prior preeclampsia increases the recurrence risk [185]. The following traditional preeclampsia risk markers for first occurrence do not influence recurrence: multiple gestation, change of partner, and long interpregnancy interval) [179], [184], [197], [198] and [199]. Women with prior preeclampsia are as likely to have gestational hypertension (median 22%) as preeclampsia (median 15%) in their next pregnancy. Women with prior gestational hypertension are more likely to experience gestational hypertension in their next pregnancy (median 21%) than preeclampsia (median 4%) [169], [171], [172] and [173]. The strongest clinical markers of preeclampsia risk identifiable at antenatal booking are recommended for screening for preeclampsia in the community [145]. Women can be offered subspecialty referral, and must receive more frequent assessments, if they have one strong risk factor (bolded in Table 5), or two or more minor risk factors (Table 5).